Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, October 19, 2023
[ Thu, Oct 19th 2023
] - WOPRAI
[ Thu, Oct 19th 2023
] - WOPRAI
[ Thu, Oct 19th 2023
] - WOPRAI
[ Thu, Oct 19th 2023
] - WOPRAI
[ Thu, Oct 19th 2023
] - WOPRAI
[ Thu, Oct 19th 2023
] - WOPRAI
[ Thu, Oct 19th 2023
] - WOPRAI
[ Thu, Oct 19th 2023
] - WOPRAI
[ Thu, Oct 19th 2023
] - WOPRAI
[ Thu, Oct 19th 2023
] - WOPRAI
[ Thu, Oct 19th 2023
] - WOPRAI
[ Thu, Oct 19th 2023
] - WOPRAI
[ Thu, Oct 19th 2023
] - WOPRAI
[ Thu, Oct 19th 2023
] - WOPRAI
[ Thu, Oct 19th 2023
] - WOPRAI
[ Thu, Oct 19th 2023
] - WOPRAI
[ Thu, Oct 19th 2023
] - WOPRAI
[ Thu, Oct 19th 2023
] - WOPRAI
[ Thu, Oct 19th 2023
] - WOPRAI
[ Thu, Oct 19th 2023
] - WOPRAI
[ Thu, Oct 19th 2023
] - WOPRAI
[ Thu, Oct 19th 2023
] - WOPRAI
[ Thu, Oct 19th 2023
] - WOPRAI
[ Thu, Oct 19th 2023
] - WOPRAI
[ Thu, Oct 19th 2023
] - WOPRAI
[ Thu, Oct 19th 2023
] - WOPRAI
[ Thu, Oct 19th 2023
] - WOPRAI
[ Thu, Oct 19th 2023
] - WOPRAI
[ Thu, Oct 19th 2023
] - WOPRAI
[ Thu, Oct 19th 2023
] - WOPRAI
Vamil Divan Reiterated (ANIP) at Strong Buy and Held Target at $72 on, Oct 19th, 2023
Vamil Divan of Guggenheim, Reiterated "ANI Pharmaceuticals, Inc." (ANIP) at Strong Buy and Held Target at $72 on, Oct 19th, 2023.
Vamil has made no other calls on ANIP in the last 4 months.
There are 2 other peers that have a rating on ANIP. Out of the 2 peers that are also analyzing ANIP, 0 agree with Vamil's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Vamil
- Oren Livnat of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $73 on, Tuesday, August 22nd, 2023
- Gregory Fraser of "Truist Securities" Reiterated at Strong Buy and Held Target at $70 on, Monday, August 21st, 2023
